Oct, 1, 2023

Vol.30 No.2, pp. 84-88


Review

  • Korean Journal of Biological Psychiatry
  • Volume 5(1); 1998
  • Article

Review

Korean Journal of Biological Psychiatry 1998;5(1):138-41. Published online: Jan, 1, 1998

A Case of Risperidone-induced Neuroleptic Malignant Syndrome

  • Hwa-Yeon Kang, MD;Yong-Ku Kim, MD, PhD; and Min Soo Lee, MD, PhD
    Department of Psychiatry, College of Medicine, Korea university, Seoul, Korea
Abstract

Neuroleptic malignant syndrome(NMS) is an uncommon but potentially fatal idiosyncratic reaction to neuroleptics, characterized by muscular rigidity, fever, autonomic dysfunction, and altered consciousness. The major theories to explain NMS is central dopaminergic blockade, but it is unclear. Risperidone is a new antipsychotic drug, a benzisoxazole derivative that blocks dopamine D2 receptor and serotonin type 2 receptor. The comparatively greater serotonin-blocking activity is believed to give risperidone the specific property of not causing any more extrapyramidal side effects than conventional antipsychotics at the optimal dose of 4-8mg/day. It is postulated that risperidone is unlikely to cause NMS. Here, we report a case of risperidone induced neuroleptic malignant syndrome.

Keywords Risperidone;Neuroleptic malignant syndrome.